Phathom Pharmaceuticals Stock Performance
| PHAT Stock | USD 7.95 0.37 4.45% |
Phathom Pharmaceuticals holds a performance score of 10 on a scale of zero to a hundred. The company holds a Beta of 2.49, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Phathom Pharmaceuticals will likely underperform. Use Phathom Pharmaceuticals standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to analyze future returns on Phathom Pharmaceuticals.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Phathom Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Phathom Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.45) | Five Day Return (6.91) | Year To Date Return 8.46 | Ten Year Return (67.68) | All Time Return (67.68) |
1 | Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | 05/01/2025 |
2 | Acquisition by Parikh Asit of 5000 shares of Phathom Pharmaceuticals at 2.3969 subject to Rule 16b-3 | 05/07/2025 |
3 | Acquisition by Topper James N of 1120 shares of Phathom Pharmaceuticals at 3.1637 subject to Rule 16b-3 | 05/13/2025 |
4 | Acquisition by Topper James N of 6300 shares of Phathom Pharmaceuticals at 3.3205 subject to Rule 16b-3 | 05/14/2025 |
5 | Acquisition by Robert Breedlove of 33000 shares of Phathom Pharmaceuticals at 4. subject to Rule 16b-3 | 05/19/2025 |
6 | Insider Trading | 05/27/2025 |
7 | Investors Still Arent Entirely Convinced By Phathom Pharmaceuticals, Inc.s Revenues Despite 54 percent Price Jump | 06/02/2025 |
8 | Acquisition by Parikh Asit of 17500 shares of Phathom Pharmaceuticals at 4.95 subject to Rule 16b-3 | 06/03/2025 |
9 | Acquisition by Parikh Asit of 10500 shares of Phathom Pharmaceuticals subject to Rule 16b-3 | 06/05/2025 |
10 | Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA Tablets through May 3, 2032 | 06/06/2025 |
11 | Phathom Pharmaceuticals Receives Buy Rating from HC Wainwright PHAT Stock News | 06/09/2025 |
12 | Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA Tablets Through May 3, 2032 | 06/16/2025 |
13 | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 06/23/2025 |
14 | Disposition of 1692 shares by Robert Breedlove of Phathom Pharmaceuticals at 8.36 subject to Rule 16b-3 | 07/16/2025 |
15 | What drives Phathom Pharmaceuticals Inc. stock price - Phenomenal trading returns - Jammu Links News | 07/18/2025 |
| Begin Period Cash Flow | 384.3 M | |
| Total Cashflows From Investing Activities | -135 K |
Phathom Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 396.00 in Phathom Pharmaceuticals on April 22, 2025 and sell it today you would earn a total of 399.00 from holding Phathom Pharmaceuticals or generate 100.76% return on investment over 90 days. Phathom Pharmaceuticals is currently generating 1.8236% in daily expected returns and assumes 13.7879% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Phathom, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Phathom Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Phathom Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Phathom Pharmaceuticals, and traders can use it to determine the average amount a Phathom Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1323
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | PHAT | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.79 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.82 actual daily | 36 64% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Phathom Pharmaceuticals is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Phathom Pharmaceuticals by adding it to a well-diversified portfolio.
Phathom Pharmaceuticals Fundamentals Growth
Phathom Stock prices reflect investors' perceptions of the future prospects and financial health of Phathom Pharmaceuticals, and Phathom Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Phathom Stock performance.
| Return On Equity | -34.89 | ||||
| Return On Asset | -0.55 | ||||
| Operating Margin | (2.77) % | ||||
| Current Valuation | 546.27 M | ||||
| Shares Outstanding | 69.81 M | ||||
| Price To Book | 25.37 X | ||||
| Price To Sales | 6.78 X | ||||
| Revenue | 55.25 M | ||||
| Gross Profit | 70.59 M | ||||
| EBITDA | (261.52 M) | ||||
| Net Income | (334.33 M) | ||||
| Cash And Equivalents | 207.39 M | ||||
| Cash Per Share | 5.39 X | ||||
| Total Debt | 201.91 M | ||||
| Debt To Equity | 2.43 % | ||||
| Current Ratio | 9.93 X | ||||
| Book Value Per Share | (4.86) X | ||||
| Cash Flow From Operations | (266.77 M) | ||||
| Earnings Per Share | (5.18) X | ||||
| Market Capitalization | 555.02 M | ||||
| Total Asset | 378.32 M | ||||
| Retained Earnings | (1.26 B) | ||||
| Working Capital | 274.41 M | ||||
About Phathom Pharmaceuticals Performance
Assessing Phathom Pharmaceuticals' fundamental ratios provides investors with valuable insights into Phathom Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Phathom Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 146.86 | 139.52 | |
| Return On Tangible Assets | (0.88) | (0.93) | |
| Return On Capital Employed | (0.95) | (1.00) | |
| Return On Assets | (0.88) | (0.93) | |
| Return On Equity | 1.32 | 1.38 |
Things to note about Phathom Pharmaceuticals performance evaluation
Checking the ongoing alerts about Phathom Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Phathom Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Phathom Pharmaceuticals is way too risky over 90 days horizon | |
| Phathom Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Phathom Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 55.25 M. Net Loss for the year was (334.33 M) with profit before overhead, payroll, taxes, and interest of 70.59 M. | |
| Phathom Pharmaceuticals currently holds about 207.39 M in cash with (266.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39. | |
| Phathom Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: What drives Phathom Pharmaceuticals Inc. stock price - Phenomenal trading returns - Jammu Links News |
- Analyzing Phathom Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Phathom Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Phathom Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Phathom Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Phathom Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Phathom Pharmaceuticals' stock. These opinions can provide insight into Phathom Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.